泊馬度胺|T2384|TargetMol

價格	￥429	￥644	￥831
包裝	10mg	50mg	100mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2025-03-12

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:泊馬度胺	英文名稱:Pomalidomide
CAS:19171-19-8	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice./Shipping at ambient temperature.
純度規(guī)格: 99.26%	產(chǎn)品類別: 抑制劑
貨號: T2384

Product Introduction

Bioactivity

名稱	Pomalidomide
描述	Pomalidomide (CC-4047) is an anti-angiogenic and immunomodulatory agent. Pomalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN) and is commonly used in the synthesis of PROTAC products.
細(xì)胞實(shí)驗(yàn)	In vitro effects of either CC-5013 or CC-4047 as single agent or in combination with rituximab were evaluated by flow cytometric analysis. Lymphoma cell lines (1 × 10^6 cells) were exposed to either CC-5013 (5 μg/mL), CC-4047 (5 μg/mL), or vehicle control (DMRIE-C, 0.01%) alone or in combination with rituximab at a final concentration of 10 μg/mL. Following a period of incubation of 24 or 48 hours, apoptosis was assessed by staining-treated cells with FITC-labeled Annexin V and propidium iodine. All samples were analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells were scored as apoptotic if they were Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively) [2].
激酶實(shí)驗(yàn)	TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that IC50 is calculated by nonlinear regression analysis [1].
動物實(shí)驗(yàn)	These studies were carried out using a disseminated lymphoma-bearing SCID mouse xenograft model. Raji cells were harvested from confluent cultures and only suspensions with >90% viable cells were used for animal inoculation. Subsequently, on day 0, SCID mice received 1 ×10^6 Raji cells via i.v. Untreated SCID mice inoculated by i.v. injection develop symptomatic central nervous system, pulmonary, and liver metastasis that result in death from massive tumor burden and central nervous system involvement after 17 to 21 days after inoculation. A second lymphoma mouse model was used to address the significance of NK cell expansion in the biological interactions observed between rituximab and IMiDs. The second mouse lymphoma xenograft consisted of SCID mice depleted of NK cells bearing Raji cells implanted via tail vein injection as described above [2].
體外活性	方法: 多發(fā)性骨髓瘤細(xì)胞 RPMI8226 和 OPM2 用 Pomalidomide (0.01-50 μM) 處理 48 h，使用 MTT assay 檢測細(xì)胞活力。結(jié)果: Pomalidomide 在 48 h 顯著降低 RPMI8226 和 OPM2 細(xì)胞的細(xì)胞活力，IC50 值分別為 8 μM 和 10 μM。[1] 方法: 多發(fā)性骨髓瘤細(xì)胞 H929、U266 和 MM.1s 用 Pomalidomide (0.05-1 μM) 和 ACY-241 (3 μM) 處理 4 天，使用 Flow cytometry 檢測細(xì)胞凋亡。結(jié)果: 當(dāng)兩種藥物聯(lián)合治療時，相對于任何一種單一藥物，細(xì)胞凋亡顯著增加。[2]
體內(nèi)活性	方法: 為評估在腦缺血中的潛在價值，將 Pomalidomide (50 mg/kg，1% carboxy methyl cellulose) 腹腔注射給長期過度表達(dá) TNF-α 表面活性蛋白 (SP)-C 啟動子的轉(zhuǎn)基因小鼠 (SP-C/TNF-α 小鼠)，每天一次，持續(xù) 21 天。結(jié)果: Pomalidomide 顯著降低血清 TNF-α 和 IL-5水平。[3]
存儲條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice./Shipping at ambient temperature.
溶解度	H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 50 mg/mL (182.99 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5.4 mg/mL (19.76 mM), Suspension.
關(guān)鍵字	TNF-α \| Pomalidomide \| MolecularGlues \| Molecular Glues \| Ligands for E3 Ligase \| LigandforE3Ligase \| Ligand for E3 Ligase \| Inhibitor \| inhibit \| E3 ligase-recruiting Moiety \| CC4047 \| CC 4047 \| Apoptosis
相關(guān)產(chǎn)品	L-Glutamic acid \| Cysteamine hydrochloride \| Alginic acid \| Flubendazole \| L-Glutamic acid monosodium salt monohydrate \| 5-Fluorouracil \| Stavudine \| Tributyrin \| Dextran sulfate sodium salt (MW 4500-5500) \| L-Ascorbic acid sodium salt \| L-Ascorbic acid \| Sodium 4-phenylbutyrate
相關(guān)庫	經(jīng)典已知活性庫 \| 抗癌上市藥物庫 \| 抗癌活性化合物庫 \| 已知活性化合物庫 \| EMA 上市藥物庫 \| 臨床失敗化合物庫 \| 抗衰老化合物庫 \| FDA 上市藥物庫 \| 免疫/炎癥分子化合物庫 \| 藥物功能重定位化合物庫 \| 抗癌臨床化合物庫 \| 抗癌藥物庫

關(guān)鍵字：泊馬度胺|||CC-4047|TargetMol

公司簡介

上海陶術(shù)生物科技有限公司為美國Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國波士頓、德國慕尼黑的同事一起，為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部，化學(xué)事業(yè)部，生物事業(yè)部和新材料部。從虛擬篩選到實(shí)體化合物分子供應(yīng)；從商業(yè)化產(chǎn)品銷售到個性化定制合成；從對明確靶點(diǎn)的分子篩選到對明確分子的多靶點(diǎn)篩選，從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化，我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。經(jīng)過在中國市場五年的精心耕耘，我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商，為超過五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩

成立日期	2013-04-18 （13年）	注冊資本	566.2651萬人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營行業(yè)	化學(xué)試劑,生物活性小分子	經(jīng)營模式	貿(mào)易,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 13年

公司成立：13年
注冊資本：566.2651萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：小分子抑制劑，藥物篩選化合物庫，天然產(chǎn)物，活性分子化合物等
公司地址：上海市閘北區(qū)江場三路28號4樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

反式-4-[(R)-1-氨基乙基]-N-(4-吡啶基)環(huán)己烷甲酰胺二鹽酸鹽

￥530.00

3-吲哚乙酰胺|T4834|TargetMol

￥413

阿斯巴甜|T0697|TargetMol

￥196